PDF herunterladen
CC BY-NC-ND 4.0 · Horm Metab Res 2020; 52(02): 126-127
DOI: 10.1055/a-1089-8026
Letter to the Editor

Reply to Drs. Kiaei and Molinaro Regarding the Publication “Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation”

Stephanie Allelein
1   Medical Faculty, Division for Specific Endocrinology, University of Düsseldorf, Düsseldorf , Germany
,
Tanja Diana
2   Department of Medicine I, Molecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, Mainz , Germany
,
Matthias Schott
1   Medical Faculty, Division for Specific Endocrinology, University of Düsseldorf, Düsseldorf , Germany
,
George J. Kahaly
2   Department of Medicine I, Molecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, Mainz , Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Leserbrief zu:

Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and DifferentiationHorm Metab Res 2019; 51(06): 341-346
DOI: 10.1055/a-0914-0535

Dear Editor,

Drs. Kiaei and Molinaro [1] put forth two criticisms of the manuscript published by us [2]. They state that the experimental design of this study is flawed and that the authors falsely claim that negative Thyretain™ TSI Reporter BioAssay results for two Graves’ diseases patients undergoing drug treatments means the absence of stimulating antibodies. To substantiate this claim Drs. Kiaei and Molinaro point out that the manufacturer of the Thyretain TSI Reporter BioAssay clearly states in the package insert that “[t]he effects of various drug therapies on the performance of this Kit have not been established” [1]. Second, the package insert explicitly states that “[a] negative result does not exclude the possibility of the presence of TSI” and results of the test should be interpreted in conjunction with information available from other clinical information, such as physical symptoms and thyroid hormone testing, as recommended by the American Thyroid Association (ATA)”. Furthermore they state that the “authors of the manuscript did not consider the manufacturer’s warning regarding the intended patient population and the ATA guidelines regarding the interpretation of the test results in conjunction with other clinical information. Instead, the authors based their conclusions on the negative Thyretain TSI Reporter BioAssay results and ignored the patients’ clinical history of Graves’ disease.”



Publikationsverlauf

Artikel online veröffentlicht:
13. Februar 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kiaei D, Molinaro R. A Negative Thyretain TSI bioassay result does not exclude the possibility of the presence of TSI. Horm Metab Res 2020; 52: 124-125
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Allelein S, Diana T, Ehlers M. et al. Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation. Horm Metab Res 2019; 51: 341-346
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 3 Leschik JJ, Diana T, Olivo PD. et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 2013; 139: 192-200
    CrossrefPubMedGoogle Scholar
  • 4 Kahaly GJ, Diana T, Glang J. et al. Thyroid stimulating antibodies are highly prevalent in hashimoto̓s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab 2016; 101: 1998-2004
    CrossrefPubMedGoogle Scholar
  • 5 Kahaly GJ, Wuster C, Olivo PD. et al. High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with graves disease. J Clin Endocrinol Metab 2019; 104: 2561-2568
    CrossrefPubMedGoogle Scholar
  • 6 Chiovato L, Vitti P, Lombardi A. et al. Detection and characterization of autoantibodies blocking the TSH-dependent cAMP production using FRTL-5 cells. J Endocrinol Invest 1987; 10: 383-388
    CrossrefPubMedGoogle Scholar
  • 7 McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 2013; 23: 14-24
    CrossrefPubMedGoogle Scholar
  • 8 Li Y, Kim J, Diana T. et al. A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity. Clin Exp Immunol 2013; 173: 390-397
    CrossrefPubMedGoogle Scholar
  • 9 Diana T, Li Y, Olivo PD. et al. Analytical performance and validation of a bioassay for thyroid-blocking antibodies. Thyroid 2016; 26: 734-740
    CrossrefPubMedGoogle Scholar
  • 10 Diana T, Krause J, Olivo PD. et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 2017; 189: 304-309
    CrossrefPubMedGoogle Scholar
  • 11 Diana T, Olivo PD, Kahaly GJ. Thyrotropin receptor blocking antibodies. Horm Metab Res 2018; 50: 853-862
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Diana T, Wuster C, Olivo PD. et al. Performance and specificity of 6 immunoassays for TSH receptor antibodies: a Multicenter Study. Eur Thyroid J 2017; 6: 243-249
    CrossrefPubMedGoogle Scholar
  • 13 Lytton SD, Li Y, Olivo PD. et al. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 2010; 162: 438-446
    CrossrefPubMedGoogle Scholar
  • 14 Frank CU, Braeth S, Dietrich JW. et al. Bridge technology with TSH receptor chimera for sensitive direct detection of TSH receptor antibodies causing graves’ disease: analytical and clinical evaluation. Horm Metab Res 2015; 47: 880-888
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Diana T, Wuster C, Kanitz M. et al. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 2016; 39: 1159-1165
    CrossrefPubMedGoogle Scholar